Alan Shaw joined the Company in May of 2012 from VaxInnate where he was Chairman and Chief Scientific Officer. Prior to VaxInnate , Dr. Shaw was the Executive Director of Public Policy, Public Health and Medical Affairs group at the Merck Vaccine Division. Previously, Dr. Shaw was responsible for a broad range of vaccine development programs at. Merck Research laboratories, including Varivax® (chickenpox) ProQuad® (measles-mumps-rubella-varicella), RotaTeq® (rotavirus/infant diarrhea), Zostavax® (shingles), and Gardasil® (cervical cancer). Prior to joining Merck, Dr. Shaw was a Senior Program Executive at Biogen S.A in Geneva, Switzerland where he led projects on hepatitis B vaccines, malaria vaccines, cytokines and their inhibitors, and cell trafficking. Dr. Shaw served as the Chairman of the International Federation of Pharmaceutical Manufacturers’ Association Biologicals Committee and has extensive experience in national and international vaccine development and policy matters. Dr Shaw is currently on the NIH-NIAID Board of Scientific Counselors, The Hilleman Laboratory SAB, and the European Union Group 7 “ADITEC” / Novartis consortium External Advisory Board. Dr. Shaw serves as an ad-hoc reviewer for grants from the Wellcome Trust.
